For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

Aducanumab – which Biogen is developing with Japanese drugmaker Eisai – was all but abandoned in 2019 after the partners decided that two phase 3 trials of the drug were unlikely to show an ...

For some observers, the failures cast doubt on the longstanding idea that the culprit in Alzheimer’s is amyloid plaques in the brain, given that Biogen’s drug, aducanumab, and other candidates had ...

The data on aducanumab are “complex,” and the drug’s path to market was not “conventional,” he notes. “But the road to innovation is rarely straightforward, and Aduhelm is not an exception.” The US ...

Ivana Rubino works at Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States. Bruce Albala works at Eisai, Inc., 100 Tice Boulevard, Woodcliff Lake ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease. The FDA's ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...